Milestone Achieved

We’re excited to share the first cryoEM-based 3D epitope mapping results for our next-generation CXCR4 antibodies, marking a major step toward new therapeutic options in oncology and immunology. 

These antibodies from our collaboration with Bio-Rad Laboratories, combine high affinity, antagonistic functionality, and superior efficacy in migration and signaling assays.

Thanks to ATEM’s cryoEM expertise, these cryoEM structures allowed us to see exactly how these antibodies engage CXCR4, knowledge that accelerates rational design and innovation.

This milestone, powered by the synergy of the Salipro® technology, Bio-Rad’s Pioneer™ platform, and ATEM’s structural analysis, exemplifies how collaboration makes the undruggable druggable.

https://www.salipro.com/

https://www.bio-rad-antibodies.com/pioneer-antibody-library.html

https://atem.bio/

Previous
Previous

Novel Strategies for GPCR Antibody Discovery - Join the Webinar!

Next
Next

Salipro Biotech is heading to PEGS Europe 2025